DekaBank Deutsche Girozentrale increased its holdings in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 19.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,700 shares of the biotechnology company’s stock after purchasing an additional 2,100 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Aclaris Therapeutics were worth $187,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ACRS. Morgan Stanley boosted its position in Aclaris Therapeutics by 481.8% during the third quarter. Morgan Stanley now owns 383,818 shares of the biotechnology company’s stock valued at $5,573,000 after purchasing an additional 317,847 shares in the last quarter. Rhumbline Advisers boosted its position in Aclaris Therapeutics by 50.6% during the fourth quarter. Rhumbline Advisers now owns 39,490 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 13,269 shares in the last quarter. Rothschild & Co. Asset Management US Inc. boosted its position in Aclaris Therapeutics by 72.2% during the fourth quarter. Rothschild & Co. Asset Management US Inc. now owns 84,047 shares of the biotechnology company’s stock valued at $621,000 after purchasing an additional 35,249 shares in the last quarter. Prudential Financial Inc. bought a new stake in Aclaris Therapeutics during the fourth quarter valued at about $198,000. Finally, Aisling Capital Management LP bought a new stake in Aclaris Therapeutics during the fourth quarter valued at about $4,689,000. Hedge funds and other institutional investors own 91.79% of the company’s stock.

Shares of NASDAQ ACRS opened at $4.67 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.30 and a current ratio of 4.33. Aclaris Therapeutics Inc has a fifty-two week low of $4.27 and a fifty-two week high of $21.97.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.05). The business had revenue of $5.04 million during the quarter, compared to analyst estimates of $5.13 million. Aclaris Therapeutics had a negative return on equity of 78.05% and a negative net margin of 999.53%. Equities analysts predict that Aclaris Therapeutics Inc will post -2.98 EPS for the current fiscal year.

Several equities research analysts have weighed in on ACRS shares. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price target on shares of Aclaris Therapeutics in a report on Friday, March 15th. Leerink Swann started coverage on Aclaris Therapeutics in a report on Monday, May 6th. They issued an “outperform” rating for the company. ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Svb Leerink started coverage on Aclaris Therapeutics in a report on Monday, May 6th. They issued an “outperform” rating and a $13.00 price target for the company. Finally, BidaskClub downgraded Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, February 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $19.69.

In other Aclaris Therapeutics news, major shareholder James E. Flynn sold 614,710 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $6.13, for a total value of $3,768,172.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 14.80% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “DekaBank Deutsche Girozentrale Acquires 2,100 Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS)” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-acquires-2100-shares-of-aclaris-therapeutics-inc-nasdaqacrs/3043225.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Recommended Story: Does a trade war provide a risk to the global economy?

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.